Research and Development of Kangyuan Pharmaceutical

For a long time, the company has been committed to building a national first-class modern R&D Chinese medicine center. Through continuous self-development and extensive scientific and technological alliance in Industry-University-Research, the technological innovation system has been established and improved, and a number of innovative products of traditional Chinese medicine and natural medicine with definite curative effect and independent intellectual property rights have been developed around the modern disease spectrum, especially in the fields of gynecology, cardiovascular and cerebrovascular diseases, orthopedics, infectious diseases and tumors, which have broken through a number of key technologies in the traditional Chinese medicine industry and accelerated the development of traditional Chinese medicine and natural medicine. It has 33 national certificates of new Chinese medicine and 53 innovative drugs under research, and has developed high-grade modern Chinese medicines such as gambogic acid, Reduning injection and Tongan injection for new Chinese medicine injection. Among them, Guizhi Fuling Capsule passed the FDA review and was allowed to directly enter the second clinical phase, and entered the forefront of modernization and internationalization of traditional Chinese medicine.

After thousands of years, the company has become the enterprise with the largest number of new drug certificates and the largest number of Chinese medicine innovations in the same industry. In terms of intellectual property protection, the company has also developed into an enterprise with the largest number of international and domestic invention patents in the same industry, applying for domestic patents 103, foreign patents 1 1 (including PCT applications), and obtaining 64 national invention patents and 4 foreign invention patents. In 2006, the number of patents granted by the company ranked eighth among all enterprises in the country, ranking first in the national pharmaceutical industry, and it was also the only enterprise in our province that entered the top ten of invention patents granted by domestic enterprises.

R&D Center creatively applied a series of new technologies, new processes, new equipment and new accessories, and formed the modernization of quality control technology of traditional Chinese medicine led by fingerprint. Large-scale application of extraction and refining technology represented by membrane separation and countercurrent extraction; And the leading technical characteristics of serialization of new dosage forms of traditional Chinese medicine with injections and soft capsules as the main body, which laid the company's leading position in the traditional Chinese medicine industry. It has successively undertaken three "863 Plan" projects of the Ministry of Science and Technology, three national Spark Plan and Torch Plan 12 projects, two high-tech industrialization demonstration projects of the National Development and Reform Commission and two major projects of the State Economic and Trade Commission, and many products have won national, provincial and ministerial awards. Based on independent innovation, the company uses cutting-edge high-tech to conduct in-depth research on traditional Chinese medicine and develop advanced new drugs representing the modern development direction of traditional Chinese medicine; At the same time, taking the FDA certification of Guizhi Fuling Capsule as a breakthrough, the internationalization of traditional Chinese medicine will drive the modernization of traditional Chinese medicine, develop modern Chinese medicine recognized by the international modern medical science system, and comprehensively build the leading position of enterprises in the future international competition of traditional Chinese medicine.